Merck & Co., Inc. provided earnings guidance for full-year 2024. For the year, company expects sales to be between $63.1 billion and $64.3 billion, including a negative impact of foreign exchange of approximately 3% at mid-April 2024 exchange rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
130.4 USD | +2.20% | +0.90% | +19.59% |
May. 02 | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.59% | 323B | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B | |
-3.54% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024